We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
- Authors
Ruxrungtham, K; Pedro, R J; Latiff, G H; Conradie, F; Domingo, P; Lupo, S; Pumpradit, W; Vingerhoets, J H; Peeters, M; Peeters, I; Kakuda, T N; De Smedt, G; Woodfall, B; TMC125-C227 study group
- Abstract
TMC125-C227, an exploratory phase II, randomized, controlled, open-label trial, compared the efficacy and safety of TMC125 (etravirine) with an investigator-selected protease inhibitor (PI) in nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant, protease inhibitor-naïve, HIV-1-infected patients.
- Publication
HIV medicine, 2008, Vol 9, Issue 10, p883
- ISSN
1468-1293
- Publication type
Journal Article
- DOI
10.1111/j.1468-1293.2008.00644.x